Share |

Content about Emergent BioSolutions

August 6, 2015

After much thought and deliberation, the best course of action for Emergent BioSolutions (NYSE: EBS) was to spin-off its’ bioscience business into a separate publicly traded company. The new company doesn’t have a name yet (expected to be announced in early 2016) but the headquarters choice has been selected.

August 17, 2011

Rockville-based Emergent BioSolutions Inc. (NYSE:EBS) has started Phase 1b/2 clinical trials study for a new drug that it hopes will aid patients in the treatment of lymphoma.

The treatment labeled TRU-016, will be administered in combination with Rituximab and Bendamustine in patients who have relapsed from indolent B-cellLymphoma.

August 11, 2011

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

August 11, 2011

Two Rockville-based firms involved in drug development have teamed up to develop a new Tuberculosis (TB) vaccine.

Aeras a non-profit focused on developing vaccines to prevent TB and Emergent BioSolutions a biotechnology firm mostly known for its Antrax drug--BioThrax--are now entering a Phase IIb Proof-of-Concept Trial of Emergent's Modified Vaccinia virus Ankara--Antigen 85Abased TB vaccine.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

August 14, 2015

Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).

The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.

August 14, 2015

Fresh off winning a $20 million Ebola treatment contract from the Department of Health and Human Services, Gaithersburg, Md.-based Emergent BioSolutions (NYSE: EBS) has been awarded another contract, this time from Centers for Disease Control and Prevention (CDC).

The biodefense company announced that the CDC has exercised an option to increase its supply of Vaccinia Immune Globulin (VIGIV), a smallpox vaccine.

August 10, 2015

Germantown, Md-based IntrexonCorporation (NYSE: XON) continues to fuel its growth by buying viable biotechnology companies. This time the bioindustrial focused company has entered an agreement to purchase Oxitec, a spin off from Oxford University in the United Kingdom, founded in 2002.

Oxitec uses genetic engineering to control insect pests and protect crops. The technonolgy is particulary focused on control the mosquitoes and the diseases they spread.

July 28, 2015

Rockville, Md-based MacroGenics, Inc. (Nasdaq:MGNX) announced that it has advanced in the development of its’ monoclonal antibody-based therapeutics drug to treat various types of leukemia. MGD011 (also known as JNJ-64052781) dosing has commenced in a Phase 1 trial in partnership with Janssen Biotech, Inc.

July 20, 2015

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

July 20, 2015

Biodefense company Emergent BioSolutions (NYSE: EBS) won a large Biomedical Advanced Research and Development Authority (BARDA) contract to treat Ebola Monoclona.

The contract is the company's first BARDA Task Order to create an Ebola treatment under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. BARDA is an authority under the U.S. Department of Health and Human Services.

December 28, 2011

Biotechnology company, Emergent BioSolutions (NYSE:EBS) announced today that Abbott Laboratories (NYSE: ABT) has terminated an agreement between the two companies to develop and commercialize its TRU-016 program. The program is expected to eventually lead to the therapeutic drugs for lymphocytic leukemia and non-Hodgkin’s lymphoma.

December 28, 2011

Biotechnology company, Emergent BioSolutions (NYSE:EBS) announced today that Abbott Laboratories (NYSE: ABT) has terminated an agreement between the two companies to develop and commercialize its TRU-016 program. The program is expected to eventually lead to the therapeutic drugs for lymphocytic leukemia and non-Hodgkin’s lymphoma.

August 5, 2011

Rockville-based Emergent BioSolutions Inc. (NYSE: EBS) released another quarter of net income increases, dispelling the anecdotal evidence of unprofitable biotechnology companies in the region.

Net income jumped to $14.21 Million in the second quarter ended June 30, 2011 opposed to a net income of $9.81 Million in the prior quarter of 2010.